Free Trial

Silence Therapeutics (SLN) Share Price, News & Analysis

GBX 535
-5.00 (-0.93%)
(As of 11/29/2021)
Today's Range
50-Day Range
52-Week Range
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
Dividend Yield
Price Target
SLN stock logo

About Silence Therapeutics Stock (LON:SLN)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

SLN Stock Price History

SLN Stock News Headlines

Do you think trading w/emotion helps?
Holding onto our losers too long and cutting our winners at the first sign of profit. Steven recognized that the only way to really solve this problem was to build an automated trading bot using a machine that has zero emotion.
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Do you think trading w/emotion helps?
Holding onto our losers too long and cutting our winners at the first sign of profit. Steven recognized that the only way to really solve this problem was to build an automated trading bot using a machine that has zero emotion.
Is Silence Golden for This Small-Cap Biotech Stock?
Silence Therapeutics PLC ADR SLN
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
£11.35 million
Cash Flow
GBX 84.41 per share
Book Value
GBX 18.20 per share


Free Float
Market Cap
£480.35 million
Not Optionable
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Mark Andrew Rothera (Age 58)
    Pres, CEO & Exec. Director
    Comp: $521.23k
  • Dr. Giles V. Campion M.D. (Age 67)
    Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
    Comp: $436.2k
  • Mr. Craig A. Tooman M.B.A. (Age 55)
    MBA, Chief Financial Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin (Age 61)
    Sr. VP, Gen. Counsel & Chief Patent Officer
  • Ms. Linnea Elrington
    VP & Head of HR
  • Dr. John Strafford
    VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff
    Sr. VP & Head of Manufacturing
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Sr. VP & Head of Molecular Design

SLN Stock Analysis - Frequently Asked Questions

How have SLN shares performed in 2024?

Silence Therapeutics' stock was trading at GBX 535 at the beginning of the year. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535.
View the best growth stocks for 2024 here

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Monday, September, 14th. The company reported ($13.70) EPS for the quarter, topping analysts' consensus estimates of ($21.70) by $8.00.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

How do I buy shares of Silence Therapeutics?

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SLN) was last updated on 6/22/2024 by Staff

From Our Partners